P105 Activity of solithromycin (SOL) against clinical isolates of S. pneumoniae with variable susceptibilities to conventional antibiotics

Abstract

Conventional macrolide antibiotics (e.g., clarithromycin) have a long history of efficacy in respiratory tract infections and of safety in adults and children, but are now losing pace in face of the increasing resistance of S. pneumoniae. The discovery and development of ketolides (macrolides devoid of a cladinose moiety) was first considered as a promising new avenue to tackle the resistance problem [1]. However, the clinical use of telithromycin, the first clinically developed ketolide, has been quickly marred by observation of major life-threatening and organdysfunction side effects [2,3]. Solithromycin (CEM-101) [4] is a new generation fluoroketolide that is safer than telithromycin and is currently entering Phase III trials in North America and Europe [5].